—
C+
C+ The full Closelook — membership. Open the C+ overview

Insmed Inc (INSM) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Insmed Inc

INSM in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Insmed develops and sells medicines for serious and rare diseases, with commercial operations across the United States, Europe and Japan. Its approved product, Arikayce, treats a rare lung infection, and it is advancing brensocatib through late-stage trials for bronchiectasis and related inflammatory conditions. The company also runs earlier-stage programmes in inhaled pulmonary hypertension treatment, gene therapy and antibody research across respiratory and rare disease areas. It is headquartered in Bridgewater, New Jersey.
Where it sits in the stack
Insmed carries no seat in Rubin, our AI infrastructure index, because it is a biotech and sits outside the compute and hardware build-out the index tracks. It belongs instead to the healthcare sleeve of our broader Nasdaq-100 universe, held for its rare-disease drug pipeline rather than any AI-related exposure.
Who it is priced against
Our peer group holds no comparison set for this name. The comparison the market often draws is with other rare-disease and respiratory biotechs, such as Vertex Pharmaceuticals.
Why Closelook tracks it
Insmed is a Nasdaq-100 constituent but has no Rubin or Halo seat, since it falls outside our AI infrastructure coverage. It does not yet carry a Closelook score, and the diary has not quoted it in past editions.
What the diary watches
The diary watches for trial results on brensocatib and the other late-stage programmes, since a readout there would reset how the pipeline's risk is read.

Insmed Inc (INSM) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for INSM, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Roth Capital, 2026-09-15

The Street on this name

Analyst actions and the latest print for INSM from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Roth Capital — target 198 from 212 Target cut to $198 from $212 (+58% to spot) 2026-09-15

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Insmed Inc (INSM)?

Insmed Inc trades as INSM on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is INSM in a Closelook index?

Not currently — Insmed Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does INSM trade against its moving averages?

Recovery attempt under the 200-day: Trades +4.8% vs the 50-day and -9.9% vs the 200-day average, 41.7% below the 52-week high and +37.2% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Insmed Inc do?

Insmed develops and sells medicines for serious and rare diseases, with commercial operations across the United States, Europe and Japan. Its approved product, Arikayce, treats a rare lung infection, and it is advancing brensocatib through late-stage trials for bronchiectasis and related inflammatory conditions. The company also runs earlier-stage programmes in inhaled pulmonary hypertension treatment, gene therapy and antibody research across respiratory and rare disease areas. Our peer group holds no comparison set for this name. The comparison the market often draws is with other rare-disease and respiratory biotechs, such as Vertex Pharmaceuticals.

Where does Insmed Inc sit in the AI build-out?

Insmed carries no seat in Rubin, our AI infrastructure index, because it is a biotech and sits outside the compute and hardware build-out the index tracks. It belongs instead to the healthcare sleeve of our broader Nasdaq-100 universe, held for its rare-disease drug pipeline rather than any AI-related exposure. Insmed is a Nasdaq-100 constituent but has no Rubin or Halo seat, since it falls outside our AI infrastructure coverage. It does not yet carry a Closelook score, and the diary has not quoted it in past editions.

What has Wall Street done on Insmed Inc recently?

The most recent analyst action on Insmed Inc on the Closelook wire is a price target by Roth Capital on 2026-09-15 (target 198 from 212). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for INSM, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe